Latest Holden News

NET SPORE group

NET SPORE

Monday, April 13, 2026
UI Health Care receives Specialized Program of Research Excellence funding for neuroendocrine tumors.
Colin Kenny, PhD

Kenny recognized with several awards for melanoma research

Thursday, April 2, 2026
Colin Kenny, PhD, has been recognized with multiple awards, but he’s quick to shift the focus to his students. At a recent conference, members of his lab presented research examining how melanoma develops and spreads — work that not only advances the field but also earned awards for each presenter.
Ksenia Krupina, PhD

Scientists uncover enzyme that shatters chromosomes, reshapes cancer genomes

Friday, January 9, 2026
Lead study author Ksenia Krupina will join UI Health Care in 2026 to continue her research.
Garry Buettner portrait

Chemist’s lifelong research comes full circle in his own treatment

Tuesday, January 6, 2026
Garry Buettner, a scientist who spent decades researching the cancer-fighting potential of intravenous vitamin C, became a patient himself, and benefited from the very treatment he helped pioneer—demonstrating both the personal and scientific impact of his work.
Katie Colling

PhD student’s research advances treatments for uterine cancer

Monday, December 8, 2025
Katie Colling was named winner of the 2025 3MT competition.

Why there’s hope for cancer in Iowa

Tuesday, November 25, 2025
These opinions from Mark Burkard, MD, PhD, Mary Charlton, PhD, and Bradley Hiatt, DO, were originally published Nov. 22, 2025, in the Des Moines Register.

UI Health Care awarded grant for AI-enhanced clinical research project aimed at improving advanced prostate cancer care

Friday, November 7, 2025
Clinicians at the University of Iowa were recently awarded a competitive grant for a multi-faceted quality improvement project using artificial intelligence (AI) to improve advanced prostate cancer care.

How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies?

Wednesday, November 5, 2025
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.